InflaRx NV (InflaRx NV) Days Inventory : 2,137.12 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). InflaRx NV's Average Total Inventories for the three months ended in Dec. 2023 was $7.07 Mil. InflaRx NV's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.30 Mil. Hence, InflaRx NV's Days Inventory for the three months ended in Dec. 2023 was 2,137.12.

The historical rank and industry rank for InflaRx NV's Days Inventory or its related term are showing as below:

IFRX' s Days Inventory Range Over the Past 10 Years
Min: 3131.33 Med: 7801.56 Max: 7801.56
Current: 3131.33

During the past 9 years, InflaRx NV's highest Days Inventory was 7801.56. The lowest was 3131.33. And the median was 7801.56.

IFRX's Days Inventory is ranked worse than
96.46% of 650 companies
in the Biotechnology industry
Industry Median: 192.335 vs IFRX: 3131.33

InflaRx NV's Days Inventory increased from Dec. 2022 (0.00) to Dec. 2023 (2,137.12). It might indicate that InflaRx NV's sales slowed down.

Warning Sign:

If a company builds up inventory, it may mean it is having difficulties selling its goods.

Inventory Turnover measures how fast the company turns over its inventory within a year. InflaRx NV's Inventory Turnover for the three months ended in Dec. 2023 was 0.04.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. InflaRx NV's Inventory-to-Revenue for the three months ended in Dec. 2023 was 3,536.50.

InflaRx NV Days Inventory Historical Data

The historical data trend for InflaRx NV's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Days Inventory Chart

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Inventory

Get a 7-Day Free Trial

7,801.56

InflaRx NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Inventory	Get a 7-Day Free Trial															-	-	-	398.55	2,137.12

Competitive Comparison of InflaRx NV's Days Inventory

For the Biotechnology subindustry, InflaRx NV's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Days Inventory distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Days Inventory falls into.

InflaRx NV Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

InflaRx NV's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0	+	12.397)	/	1 )	/	0.58	*	365
=	12.397					/	0.58	*	365
=	7,801.56

InflaRx NV's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

	Days Inventory (Q: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (1.749	+	12.397)	/	2 )	/	0.302	*	365 / 4
=	7.073					/	0.302	*	365 / 4
=	2,137.12

InflaRx NV (NAS:IFRX) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

InflaRx NV's Inventory Turnover for the three months ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0.302	/	7.073
	=	0.04

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

InflaRx NV's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	7.073	/	0.002
	=	3,536.50

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

InflaRx NV Days Inventory Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.